ALNYLAM PHARMS INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALNYLAM PHARMS INC, and what generic alternatives to ALNYLAM PHARMS INC drugs are available?
ALNYLAM PHARMS INC has four approved drugs.
There are forty-four US patents protecting ALNYLAM PHARMS INC drugs.
There are seven hundred and seventy-seven patent family members on ALNYLAM PHARMS INC drugs in fifty-four countries and seventy-nine supplementary protection certificates in seventeen countries.
Summary for ALNYLAM PHARMS INC
International Patents: | 777 |
US Patents: | 44 |
Tradenames: | 4 |
Ingredients: | 4 |
NDAs: | 4 |
Drugs and US Patents for ALNYLAM PHARMS INC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alnylam Pharms Inc | AMVUTTRA | vutrisiran sodium | SOLUTION;SUBCUTANEOUS | 215515-001 | Jun 13, 2022 | RX | Yes | Yes | 9,399,775 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | RX | Yes | Yes | 9,631,193 | ⤷ Sign Up | ⤷ Sign Up | ||||
Alnylam Pharms Inc | AMVUTTRA | vutrisiran sodium | SOLUTION;SUBCUTANEOUS | 215515-001 | Jun 13, 2022 | RX | Yes | Yes | 9,370,581 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALNYLAM PHARMS INC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 8,895,718 | ⤷ Sign Up |
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 8,895,721 | ⤷ Sign Up |
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 8,362,231 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ALNYLAM PHARMS INC Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Peru | 20161130 | ⤷ Sign Up |
China | 107106874 | ⤷ Sign Up |
European Patent Office | 2238251 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ALNYLAM PHARMS INC Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3204015 | C202230012 | Spain | ⤷ Sign Up | PRODUCT NAME: LUMASIRAN, OPCIONALMENTE EN FORMA DE UNA SAL; NATIONAL AUTHORISATION NUMBER: EU/1/20/1496; DATE OF AUTHORISATION: 20201119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1496; DATE OF FIRST AUTHORISATION IN EEA: 20201119 |
3329002 | 23C1008 | France | ⤷ Sign Up | PRODUCT NAME: VUTRISIRAN DANS TOUTES LES FORMES RELEVANT DE LA PROTECTION DU BREVET DE BASE; REGISTRATION NO/DATE: EU/1/22/1681 20220916 |
3052628 | 301061 | Netherlands | ⤷ Sign Up | PRODUCT NAME: GIVOSIRAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/20/1428 20200304 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.